Tenalisib

DB15295InvestigationalSmall molecule

Tenalisib is under investigation in clinical trial NCT03711604 (Compassionate Use Study of Tenalisib (RP6530)).

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform and Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Curator reviewed
Formula / weight: C₂₃H₁₈FN₅O₂ · 415.428 g/mol (avg)
Also known as: (S)-2-(1-(9H-Purin-6-Ylamino)Propyl)-3-(3-Fluorophenyl)-4H-Chromen-4-One) · 3-(3-FLUOROPHENYL)-2-((1S)-1-((7H-PURIN-6-YL)AMINO)PROPYL)-4H-1-BENZOPYRAN-4-ONE · 4H-1-BENZOPYRAN-4-ONE, 3-(3-FLUOROPHENYL)-2-((1S)-1-(9H-PURIN-6-YLAMINO)PROPYL)-

Resolves to

Compound

Structure

InChIKeyHDXDQPRPFRKGKZ-INIZCTEOSA-NSMILESCC[C@H](NC1=C2N=CNC2=NC=N1)C1=C(C(=O)C2=CC=CC=C2O1)C1=CC=CC(F)=C1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tenalisib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.